Abstracts & Manuscripts Allurion Literature Allurion Literature - Abstracts Multicenter Studies Demonstrating Safety & Efficacy Allurion Program vs Lifestyle Intervention alone Long Term Weight Maintenance Sequential Allurion Balloon Program Diabetes Remote Follow - up using Telehealth Adolescents Multicenter Studies Demonstrating Safety & Efficacy 4 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² ² Allurion Program vs Lifestyle Intervention alone 5 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² Long Term Weight Maintenance (1/2) 6 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² ² Long Term Weight Maintenance (2/2) 7 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² Sequential Allurion Balloon Program 8 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² ² Diabetes 9 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² Remote Follow - up using Telehealth 10 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² Adolescents 11 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² Allurion Literature - Manuscripts Meta - Analyses and Registry Studies Safety and efficacy data from around the world – LATAM Safety and efficacy data from around the world – MEA Safety and efficacy data from around the world - Europe Symptom Management Cost - effectiveness of the Allurion Balloon Meta - Analyses and Registry Studies (1/2) 13 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² Meta - Analyses and Registry Studies (2/2) 14 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² Safety and efficacy data from around the world - LATAM 15 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² Safety and efficacy data from around the world – MEA (1/2) 16 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² ² Safety and efficacy data from around the world – MEA (2/2) 17 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² ² Safety and efficacy data from around the world – Europe (1/2) 18 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² ² Safety and efficacy data from around the world – Europe (2/2) 19 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ² ² ² Symptom Management 20 © 2022 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL Citation Sample size (N) Methods Demographics Results Conclusions ²